Zydus Cadila gets USFDA's final approval to market antidepressant drug

Drug firm Zydus Cadila has received final approval from the US health regulator to market Amitriptyline hydrochloride tablets used for treatment of depression in the American market.

The company has received final approval from the United States Food and Drug Administration (USFDA) to market the tablets in strengths of 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg, Cadila Healthcare, the listed entity of the group said in a BSE filing today.

The drug, used in treating depression, will be manufactured at the group's formulations facility at SEZ Ahmedabad, it added.

"The group now has more than 160 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of the filing process by the company," it added.

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel